US 11,000,216 C1 (12,771st)
Medical device inserters and processes of inserting and using medical devices
Samuel M. Curry, Oakland, CA (US); Manuel L. Donnay, San Francisco, CA (US); Tuan Nguyen, Dublin, CA (US); Louis G. Pace, San Carlos, CA (US); Peter G. Robinson, Alamo, CA (US); and Phillip Yee, San Francisco, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Reexamination Request No. 90/019,331, Dec. 11, 2023.
Reexamination Certificate for Patent 11,000,216, issued May 11, 2021, Appl. No. 17/030,030, Sep. 23, 2020.
Application 90/019,331 is a continuation of application No. 14/996,751, filed on Jan. 15, 2016, granted, now 10,881,340.
Application 14/996,751 is a continuation of application No. 13/071,487, filed on Mar. 24, 2011, granted, now 9,265,453.
Claims priority of provisional application 61/411,262, filed on Nov. 8, 2010.
Claims priority of provisional application 61/361,374, filed on Jul. 2, 2010.
Claims priority of provisional application 61/345,562, filed on May 17, 2010.
Claims priority of provisional application 61/317,243, filed on Mar. 24, 2010.
Ex Parte Reexamination Certificate issued on Nov. 14, 2024.
Int. Cl. A61B 5/151 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61B 5/15 (2006.01); A61B 5/157 (2006.01); A61B 17/34 (2006.01); A61M 5/158 (2006.01); A61B 5/01 (2006.01); A61B 17/00 (2006.01)
CPC A61B 5/150022 (2013.01) [A61B 5/1411 (2013.01); A61B 5/14503 (2013.01); A61B 5/14532 (2013.01); A61B 5/14542 (2013.01); A61B 5/14546 (2013.01); A61B 5/150259 (2013.01); A61B 5/150282 (2013.01); A61B 5/150396 (2013.01); A61B 5/150419 (2013.01); A61B 5/150427 (2013.01); A61B 5/150511 (2013.01); A61B 5/15087 (2013.01); A61B 5/15107 (2013.01); A61B 5/15113 (2013.01); A61B 5/15117 (2013.01); A61B 5/1513 (2013.01); A61B 5/15186 (2013.01); A61B 5/1519 (2013.01); A61B 5/15194 (2013.01); A61B 5/157 (2013.01); A61B 5/6848 (2013.01); A61B 5/6865 (2013.01); A61B 17/34 (2013.01); A61B 17/3468 (2013.01); A61M 5/158 (2013.01); A61B 5/00 (2013.01); A61B 5/0002 (2013.01); A61B 5/01 (2013.01); A61B 5/15016 (2013.01); A61B 5/150732 (2013.01); A61B 2017/00384 (2013.01); A61B 2560/063 (2013.01); A61M 2005/1585 (2013.01)]
OG exemplary drawing
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
The patentability of claims 1-3 is confirmed.
Claims 4-29 were not reexamined.
1. A glucose monitoring system comprising:
an insertion assembly for inserting a glucose sensor into a subject, the insertion assembly comprising:
the glucose sensor, wherein a distal end of the glucose sensor is configured to be inserted under skin of the subject;
a distal surface including an adhesive layer, wherein the distal surface is configured to be positioned on the skin of the subject such that the adhesive layer adheres to the skin of the subject;
an interior of the insertion assembly including a first spring in a loaded position, a second spring, a sliding member, and a straight track having a length, wherein the sliding member is configured to move only within the straight track; and
a button configured to be pressed along a first axis toward the interior of the insertion assembly,
wherein the button is further configured to release the first spring from the loaded position upon being pressed, such that the first spring causes the sliding member to move within the straight track along a second axis different from the first axis, wherein the second axis is defined by the length of the straight track,
wherein movement of the sliding member within the straight track causes advancement of a sharp and the glucose sensor in a distal direction along an insertion axis different from the first axis and the second axis such that the distal end of the glucose sensor is inserted under the skin of the subject,
wherein the sliding member is further configured to continue moving within the straight track after the advancement of the sharp and the glucose sensor in the distal direction along the insertion axis,
wherein the second spring is configured to expand and retract the sharp in a proximal direction along the insertion axis while the distal end of the glucose sensor remains under the skin of the subject,
wherein the insertion assembly comprises a maximum height measured parallel with the insertion axis and a maximum width measured parallel with the length of the straight track, and wherein the maximum height is greater than the maximum width,
wherein the second spring is a compression spring, and
wherein the glucose sensor is configured to operate for a period of about seven days or more.